Author: Poole, Stephen; Clark, Tristan W.
Title: Rapid syndromic molecular testing in pneumonia: The current landscape and future potential Cord-id: rbblg4pu Document date: 2019_12_3
ID: rbblg4pu
Snippet: Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antib
Document: Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia.
Search related documents:
Co phrase search for related documents- additional cost and low prevalence: 1
- adenovirus influenza and low prevalence: 1, 2, 3, 4, 5
- adenovirus influenza and low respiratory tract: 1
- adenovirus influenza and low sensitivity: 1, 2
- adenovirus influenza and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- low prevalence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- low respiratory tract and lung disease: 1, 2, 3
- low sensitivity and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- lung disease and machine failure: 1
Co phrase search for related documents, hyperlinks ordered by date